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AbstrAct
Background: Potential drug–drug interactions (pDDIs) may not manifest clinically in patients who are treated with 
multiple pharmaceutical agents, but when they do they can produce adverse outcomes. In patients with chronic 
kidney disease (CKD), the frequent use of multiple agents to manage this condition and its complications puts 
these patients at increased risk for DDIs. We determined the prevalence of pDDIs in CKD patients in two Nigerian 
hospitals and investigated possible predictors of pDDIs.
Methods: This cross-sectional study involved patients with CKD who attended the nephrology unit of the University 
of Maiduguri Teaching Hospital and the medical outpatients clinic of the State Specialist Hospital in Maiduguri, 
Nigeria. We collected prescriptions, clinical data and laboratory data from the medical files of patients seen between 
January 2013 and December 2017. Descriptive and inferential statistics were used to analyse the data.
Results: The study included 201 patients. A total of 273 pDDIs were identified in 166 patients (83%). These pDDIs 
included 30 unique drug interactions, the most common being between ferrous sulphate and calcium carbonate 
(seen in 46% of patients with pDDIs), followed by lisinopril and furosemide (8%). The proportion of clinically 
significant interactions was only 2%. There was a positive association between pDDIs and the total number of drugs 
prescribed (P  <  0.001).
Conclusions: A high prevalence of pDDIs was documented among Nigerian patients with CKD. The bulk of 
the interactions were related to the co-prescription of ferrous sulphate and calcium carbonate. The total number 
of drugs prescribed was a significant predictor of pDDIs. We recommend routine screening of prescriptions of 
CKD patients for potential pDDIs. 
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INtrODUctION
Chronic kidney disease (CKD) is one of the main global 
health problems, especially in developing nations. Its pre-
valence in Nigeria ranges from 6% to 12% [1-4]. Patients 
with CKD are at increased risk for drug–drug interactions 
(DDIs) because of the use of multiple pharmaceutical 
agents and alterations in their pharmacodynamics and 
pharmacokinetics [5]. Not all potential DDIs (pDDIs) 
may manifest clinically, but when they do they can pro-
duce adverse outcomes such as treatment failure or 
drug-induced toxicity with resultant increased costs, 
morbidity and even mortality [6-9]. The pDDI refers to 
the likelihood of a drug altering the effects of another 
when both are administered simultaneously [10]. The 
reported prevalence of pDDIs in CKD populations 
ranges from 76% to 89% [11-16]. This underscores the 
need for clinicians to always screen for pDDIs in this 
high-risk population.
As kidney function deteriorates in patients with CKD, 
more medications are needed to control the many com-
plications of this disease, such as metabolic and bone 
disorders, anaemia, dyslipidaemia and cardiovascular dis-
orders [6]. The main factor associated with pDDIs in 
CKD patients is, therefore, polypharmacy [17].   
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An earlier study on pDDIs among CKD patients in the 
southwestern part of Nigeria reported a high prevalence 
of 96% [18], while another study from the southeastern 
part of the country reported a prevalence of 64.0% [17]. 
We aimed to determine the prevalence and predictors of 
pDDIs among CKD patients in northeastern Nigeria.
MEtHODs
This study was a cross-sectional audit of the prescrip- 
tions of CKD patients who attended the nephrology unit 
of the University of Maiduguri Teaching Hospital and the 
medical outpatients unit of the State Specialist Hospital in 
Maiduguri, Nigeria, from January 2013 to December 2017. 
All patients diagnosed with CKD (stages 1–5, including 
those on dialysis), who had at least two oral medications 
concurrently prescribed, comprised the study population. 
Data extracted from the patients’ medical f iles included 
their demographic information, concurrent medications, 
and clinical characteristics such as comorbidities (other 
chronic diseases) and last recorded serum creatinine. 
Estimated glomerular filtration rate (eGFR) was calculated 
from serum creatinine using the Modification of Diet in 
Renal Disease (MDRD) equation. The eGFR (in mL/
min/1.73 m2) was used to group patients into different 
CKD stages: stage 1, eGFR ≥ 90; stage 2, eGFR 60–89; 
stage 3a, eGFR 45–59; stage 3b, eGFR 30–44; stage 4, 
eGFR 15–29; stage 5, eGFR < 15 [19]. Each patient’s list of 
medications was screened using the Omnio® drug inter-
action checker [20]. The identif ied pDDIs were graded 
according to their level of severity. Each pDDI was 
categorized as “moderate" (use only in special circum-
stances), “severe” (potential for serious interactions – 
regular monitoring required or use of alternative 
medication) or “contraindication” (should be avoided; the 
risk outweighs the benefit).   
Descriptive statistics (frequency, percentage, mean ± 
standard deviation (SD), range) were used to summarize 
the data. Comparisons among patients with and without 
pDDI were performed using the chi-square test for 
categorical variables and Student’s t-test for numerical 
variables. Multiple linear regression was used to investi-
gate the predictors of pDDIs. A P value < 0.05 was 
considered statistically signif icant. Statistical Package for 
Social Sciences (SPSS) for Windows® version 21.0 (SPSS 
Inc, Chicago, USA) was used for the analyses.
The Research and Ethics Committees of the study 
hospitals granted the ethical clearance with approval 
numbers UMTH/REC/17/118 and SSH/GEN/641.
rEsULts
Table 1 presents the demographic data of the study 
population. There were 201 CKD patients included, with 
66% being female. Most were between 40–59 years old 
and the mean age was 49.5 years. Hypertension (35%) 
was the most common comorbidity encountered and 
about 70% of the patients were at CKD stage 5. Four 
hundred and twenty-eight prescriptions containing at 
least two concurrent prescribed oral medications were 
examined. Most patients (85%) used 5 or more drugs 
with a mean of 5.8 ± 1.5 and a range of 2–9 drugs. 
Two hundred and seventy-three pDDIs were observed in 
166 (83%) patients. The mean number of pDDIs per 
patient in this group was 1.4 ± 1.0, with a range of 1–5. 
The majority (87%) had one or two pDDIs, and only 1.2% 
had 5 pDDIs (Figure 1).
Of the 273 pDDIs, 98% were of moderate severity, 0.4% 
were severe interactions, and 1.8% were for contraindi-
cated drug combinations. We identified 30 different drug 
interacting combinations, ferrous sulphate plus calcium 
carbonate (in 46%) being the most frequent combination 
encountered. The prevalence of highly clinically significant 
interactions was only 1.8%. The pDDIs identified by this 
study and their potential adverse outcomes are listed in 
Table 2.
Multiple linear regression analysis (Table 3) revealed a 
positive relationship between the number of pDDIs and 
the total number of drugs prescribed (P < 0.001).
DIscUssION
This study found a high prevalence of pDDIs in our CKD 
population, with most being of moderate severity and few 
of high clinical importance. The number of medications 
prescribed for each patient was a major predictor of 
pDDIs.       
In our study, the prevalence and severity of pDDIs in CKD 
patients was similar to that reported by an earlier study 
conducted in the southwestern part of the country [18]. 
That study also reported a low prevalence of contraindi-
cated drug combinations (0.1%) [18]. A similar prevalence 
has been reported in India, Palestine and Pakistan [12-14] 
whereas lower prevalence rates have been reported in 
Brazil and India (56.9% and 66.8%, respectively) [11,21]. 
Variations in the prescribing habits of physicians across 
countries and hospitals could be responsible for this 
observed difference. Regarding the severity of pDDIs, 
studies from many countries have reported high rates of 
pDDIs of moderate severity [11,12,14-16].  
The mean number of pDDIs per affected patient recorded 
by our study is similar to the 1.5 reported in an earlier inves-
tigation from the southwestern part of the country [18], 
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but lower than the range of 2.7–4.1 reported in other 
studies [12,15,21]. The differences from studies outside 
Nigeria may relate to variations in the prescribing habits of 
physicians of different nations.  
The most frequent interacting drug combinations identified 
in our study was calcium carbonate and ferrous sulphate. 
Concomitant use of calcium may decrease the intestinal 
absorption of orally administered iron. Therefore, when 
these two drugs are co-prescribed for CKD patients, 
physicians and pharmacists should counsel these patients 
to take the ferrous sulphate at least two hours apart 
from the calcium carbonate, to prevent this unwanted 
interaction. This f inding is in agreement with some studies 
[11,16,18], but differs from others, which reported ascor-
bic acid/cyanocobalamin, calcium carbonate/amlodipine, 
ferrous sulphate/omeprazole, lisinopril/furosemide, or 
aspirin/clopidogrel as the most frequent combinations for 
pDDIs [12-14,17,21].     
The number of prescribed medications was a significant 
predictor of pDDIs in our study, consistent with the results 
of others [14,17,22]. Physicians prescribing medications 
for these patients should ensure rational prescribing and 
avoidance of unnecessary medications to reduce the pill 
burden and the risk of DDIs in this patient population. The 
use of clinical decision support systems could assist in this 
regard. Clinical pharmacists should also screen prescriptions 
for pDDIs before dispensing medications to CKD patients 
and, when minor or moderate interactions are detected, 
patients should be counselled on how to separate the 
administration of the drugs that are involved. 
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table 1.  Distribution of patients with CKD by occurrence of potential drug–drug interactions (pDDis).
Variable all patientsn = 201 (%)
With pDDis
n = 166 (%)
Without pDDis
n = 35 (%) P value
Hospital category
Secondary 100 (49.8) 74 (44.6) 26 (74.3) 0.001
Tertiary 101 (50.2) 92 (55.4) 9 (25.7)
Sex
Female 133 (66.2) 110 (66.3) 23 (65.7) 0.950
Male 68 (33.8) 56 (33.7) 12 (34.3)
age in years 49.5 ± 14.5 48.9 ± 14.0 52.1 ± 16.8 0.244
CKD stage
3 19 (9.5) 17 (10.2) 2 (5.7) 0.309
4 43 (21.4) 38 (22.9) 5 (14.3)
5 139 (69.2) 111 (66.9) 28 (80.0)
number of comorbidities
None 95 (47.3) 9 (5.4) 2 (5.7) 0.016
1 95 (47.3) 71 (42.8) 24 (68.6)
≥2 11 (5.5) 86 (51.8) 9 (25.7)
number of drugs (SD) 5.8 (1.5) 6.1 (1.3) 4.5 (1.5) < 0.001
Range 2–9 3–9 2–8
Figure 1.  Distribution of patients with one or more 
potential drug–drug interactions (pDDis).
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table 2.  Potential drug–drug ınteractions among patients with chronic kidney disease.
Severity level Object drug_precipitant drug n (%) Potential adverse outcomes
Contraindication*
N = 5 (1.8%)
coartem_ciprofloxacin 5 (1.8)
Increased risk of QTc-interval prolongation and 
life-threatening cardiac arrhythmias
Severe                                            
N = 1 (0.4%)
erythromycin_amlodipine 1 (0.4)
Increased risk of hypotension, shock, acute kidney 
failure, and sudden death
Moderate                                             
N = 267 (97.8%)
ferrous sulphate_calcium carbonate 125 (45.8) Decreased absorption of iron
lisinopril_furosemide 21 (7.7) Severe postural hypotension
captopril_furosemide 18 (6.6) Severe postural hypotension
captopril_spirinolactone 18 (6.6) Hyperkalaemia
ciprofloxacin_ferrous sulphate 14 (5.1) Decreased effectiveness of ciprofloxacin
ferrous sulphate_antacid 14 (5.1) Decreased absorption of iron
methyldopa_ferrous sulphate 10 (3.7) Decreased efficacy of methyldopa
ciprofloxacin_calcium carbonate 7 (2.6) Decreased effectiveness of ciprofloxacin
lisinopril_aspirin 7 (2.6) Decreased antihypertensive effects of lisinopril
diclofenac_furosemide 5 (1.8)
Decreased antihypertensive and diuretic  
actions of furosemide
lisinopril_ spirinolactone 4 (1.5) Hyperkalaemia
ciprofloxacin_antacid 3 (1.1) Decreased effectiveness of ciprofloxacin
captopril_aspirin 2 (0.7) Decreased antihypertensive effects of captopril
captopril_diclofenac 2 (0.7)
Decreased antihypertensive effects of captopril and 
deterioration of renal clearance
levofloxacin_ferrous sulphate 2 (0.7) Decreased effectiveness of levofloxacin
lisinopril_torsemide 2 (0.7) Severe postural hypotension
losartan_furosemide 2 (0.7) Severe postural hypotension
atenolol_nifedipine 1 (0.4) Increased toxic effects of both drugs
atenolol_prazocin 1 (0.4) Increased hypotensive action of prazocin
cefuroxime_calcium carbonate 1 (0.4) Decreased efficacy of cefuroxime
ciprofloxacin_multivitamins 1 (0.4) Decreased effectiveness of ciprofloxacin
digoxin_furosemide 1 (0.4) Increased arrhythmias
levofloxacin_calcium carbonate 1 (0.4) Decreased effectiveness of levofloxacin
levofloxacin_multivitamins 1 (0.4) Decreased effectiveness of levofloxacin
lisinopril_diclofenac 1 (0.4) Decreased antihypertensive effects of lisinopril
lisinopril_naproxen 1 (0.4) Decreased antihypertensive effects of lisinopril
phenytoin_calcium carbonate 1 (0.4) Decreased levels and effectiveness of phenytoin
risperidone_levofloxacin 1 (0.4)
Increased risk of QTc-interval prolongation  
and arrhythmias
* Interaction which is highly clinically significant. Use of this drug combination is contraindicated.
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Among the limitations of our study is the fact that we 
detected only pDDIs, which may not manifest clinically. 
Another is that the Omnio® drug interaction checker used 
does not take into consideration the prescribed dose, 
frequency of administration, route of administration, and 
duration of medication use.   
cONcLUsIONs
There is a relatively high prevalence of pDDIs among 
patients with CKD in northeastern Nigeria. Most were of 
moderate severity, and the most common was between 
calcium carbonate and ferrous sulphate. The number of 
medications prescribed for each patient was a significant 
predictor of pDDIs and we therefore recommend that 
physicians and pharmacists attending to these patients 
should use clinical decision support systems or drug–drug 
interaction software to detect and prevent detrimental 
pDDIs. 
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table 3.  Multivariable analysis of factors associated with number of potential drug–drug interactions.
Variable Coefficient P value 95% confidence interval
Hospital category 0.016  0.830 –0.263 0.328
Number of drugs prescribed 0.409 < 0.001 0.184 0.394
Number of comorbidities 0.134  0.051 –0.001 0.313
